 BRYAN, Texas, July 15, 2021 GLOBE NEWSWIRE -- iBio, Inc. NYSEA:IBIO iBio or the Company, a biotech innovator and biologics contract manufacturing organization, today announced that preclinical studies of IBIO-202, its subunit vaccine candidate that targets the nucleocapsid protein N protein of SARS-CoV-2, demonstrated a robust, antigen-specific, memory T-cell response. 